The efficacy of an intramammary antibiotic dry cow preparation with significant gram-negative spectrum (product A; Leo Red Dry Cow, Leo Animal Health, UK) was compared with a product with no gram-negative efficacy (product B; Orbenin Extra DC, Pfizer Ltd, UK) as assessed by control of coliform mastitis in the first 100 d of the lactation. The efficacy of both products was also compared for control of noncoliform mastitis and for the ability to control existing and new intramammary infections as measured by individual cow somatic cell counts. Cows treated with product A were significantly less likely to develop clinical Escherichia coli or coliform mastitis during the dry period or the first 100 d of lactation than cows treated with product B. Cows treated with product A were no more likely to develop clinical mastitis due to a noncoliform organism than were cows treated with product B. There was no significant difference between the two groups as measured by individual cow somatic cell count changes across the dry period. This study is the first to have demonstrated the clinical efficacy of an intramammary antibiotic dry cow preparation, as measured by reduction in gramnegative clinical mastitis in the subsequent lactation. These findings demonstrate that selection of a dry cow intramammary preparation with a significant gramnegative spectrum can influence the incidence of clinical coliform mastitis in the subsequent lactation. This finding should be one of the factors taken into account when selecting products. (Key words: dry cow therapy, coliforms, mastitis) Abbreviation key: SCC-POST = individual cow geometric mean SCC before drying off, SCC-PRE = individual cow geometric mean SCC after calving.
INTRODUCTION
Antibiotic dry cow therapy has two functions; firstly to remove preexisting IMI present at drying off and to prevent new IMI during the nonlactating period (Smith et al., 1966) . Initially developed in the 1940s to aid in the control of summer mastitis (Pearson, 1950 (Pearson, , 1951 , antibiotic dry cow therapy was adopted as a cornerstone of mastitis control strategies in the 1960s (Smith et al., 1966) and was classically directed against the contagious pathogens. Therefore, dry cow intramammary infusion products typically contain antibiotics with a predominantly gram-positive spectrum.
Widespread implementation of the five-point plan over the last 30 yr has since resulted in a change in the incidence and etiology of clinical mastitis in the United Kingdom. Despite a decline in the overall incidence of mastitis, environmental pathogens such as the coliforms and Streptococcus uberis have become an increasingly significant cause of disease, while the incidence of the contagious pathogens, such as Streptococcus agalactiae and Staphylococcus aureus, has decreased (Booth, 1997; Green and Bradley, 1998; Bradley and Green, 2001a) . The increased incidence of environmental pathogens has renewed interest in the epidemiology of coliform mastitis and alternate approaches to its control.
The susceptibility of the nonlactating mammary gland to coliform infection has long been recognized (Eberhart and Buckalew, 1977; Murphy and Hanson, 1943; Oliver and Mitchell, 1983; Smith et al., 1985; Todhunter et al., 1991) , although the true impact of these infections on the incidence of clinical mastitis in the subsequent lactation has only recently been established through the use of DNA fingerprinting . Experimental studies have demonstrated that infections becoming established later during the dry period are more likely to persist and result in clinical mastitis than those acquired during involution (McDonald and Anderson, 1981) .
To date, it has been assumed that antibiotic dry cow therapy could not play a role in the control of clinical coliform mastitis in early lactation (Smith et al., 1985) , primarily due to inadequate spectrum and persistence of the antimicrobial agents employed. However, a dry cow intramammary infusion product available in Europe (Leo Red Dry Cow, Leo Animal Health, UK) has a label claim for persistence above the mean inhibitory concentration of Escherichia coli for up to 14 wk after drying off. This persistent gram-negative activity is provided by framycetin, which does not adversely affect the meat and milk withdrawals of the product due to its pharmacokinetics in the mammary gland (The Compedium of Data Sheets for Veterinary Products, NOAH, UK). The aim of the research presented in this paper was to assess the impact of an intramammary antibiotic dry cow preparation with significant gramnegative activity (Leo Red Dry Cow) on the incidence of coliform mastitis in the subsequent lactation, while monitoring clinical mastitis caused by other pathogens.
MATERIALS AND METHODS

Herd Selection
Ten herds were selected on the basis of location (Somerset), nonseasonal calving pattern, three monthly geometric mean bulk milk SCC <250,000 cells/ml, and the likelihood of owner compliance with the study protocol. The herds were not selected on the basis of previous mastitis incidence or etiology. A calculation to determine the number of cows needed to provide adequate statistical power to identify a difference between the two treatment groups was based on regional data of mastitis incidence and etiology (Bradley and Green, in press ).
Herd Details
The 10 herds were between 80 and 220 cows in size. Yields were 6000 to 7000 L (305 d adjusted) and mean bulk milk SCC varied between 55,000 and 230,000 cells/ ml. Nine herds managed lactating cows on pasture during the summer months and in free stalls during the winter; the 10th herd (no. 9) managed the lactating cows in free stalls throughout the year. The dry cows in all herds were managed on pasture during the summer months and in cubicle or straw yard systems during the housing period. Periparturient cows were managed at grass or in loose boxes. No mastitis vaccines were used in any of the herds. Eight herds recorded individual cow SCC, and all 10 herds participated in a herd health recording scheme.
Cow Selection Criteria and Treatment Randomization
Cows were eligible for recruitment to the study if they had four functional quarters, had no significant teat lesions, were in good health, and had not received antibiotic or anti-inflammatory therapy within the last 30 d. The first cow on each farm was allocated to a treatment group by the toss of a coin; cows were then alternately allocated to either treatment group A (100 mg of framycetin sulphate, 100 mg of penethamate hydriodide, 300 mg of procaine penicillin; LeoRed Dry Cow, Leo Animal Health, UK) or B (600 mg of cloxacillin; Orbenin Extra Dry Cow, Pfizer Ltd, UK) as they entered the study. This method was employed to ensure that the two groups were temporally matched even when low numbers of cows were being enrolled, thus ensuring that environmental exposure was as similar as possible between the two groups. Herdspersons were blinded to product administration to further ensure that there was no bias introduced from cow selection.
Treatment Administration
All treatments were administered by the authors after the last milking, as outlined below. Following fulfillment of the enrollment criteria, the teats of enrolled cows were wiped to remove gross contamination (if necessary) and dipped in a solution containing 2800 mg/kg of available chlorine (Agrisept, Pharmacia and UpJohn, UK). After a minimum 30-s contact time, the teats were wiped dry. The teats were subsequently scrubbed with a cotton wool swab soaked in 70% ethanol and allowed to dry; foremilk was then discarded. Before the tube cannula was inserted and treatment was administered, the teat ends were scrubbed for a second time with 70% ethanol and allowed to dry. After treatment, teats were dipped in a solution containing 2800 mg/kg of available chlorine, and cows were confined to a loafing yard for at least 30 min. Disposable gloves were worn throughout the sanitization and treatment process.
Clinical Mastitis Sampling Strategy
Clinical mastitis was monitored for the first 100 d of lactation. Herdspersons were trained in the identification, grading, and sampling of clinical mastitis. Clinical mastitis was identified in quarters on the basis of the presence of abnormal secretion and (or) udder changes (e.g., pain, heat, swelling). Mastitis severity was graded according to the following system: Grade 1: milk changes only (e.g., clots), grade 2: milk and udder changes (e.g., swelling, heat), and grade 3: systemic signs (e.g., depression, pyrexia). Before antibiosis was instituted, secretion samples were collected by the same teat sanitization method employed by the authors before administration of dry cow therapy. Before they were frozen, samples were identified by farm, cow, quarter, and date; severity grades and treatment regimes were also recorded. The frozen samples were submitted for bacteriological analysis on a weekly basis. The 10 farms were each visited on a weekly basis by the authors to reinforce initial training and to encourage compliance.
Bacteriology
Samples were submitted to the Langford Veterinary Investigation Centre for bacteriological analysis. Ten microliters of secretion was inoculated onto sheep blood agar and Edward's agar; 100 µl of secretion was inoculated onto MacConkey agar to enhance the detection of Enterobacteriaceae. Plates were incubated at 37°C and read at 24 and 48 h. Organisms were identified and quantified by standard laboratory techniques (Quinn et al., 1994) . Escherichia coli was identified by colony morphology and oxidase and indole tests; other Enterobacteriaceae were identified using a microtube identification system (RapiD 20 E, bioMérieux, UK).
Additional Data Collection
Drying off dates, calving dates, and parity were recorded for all enrolled cows. Individual cow SCC were obtained from farm records for recordings in the last 4 mo of lactation before drying off. Individual cow SCC were obtained from farm records for recordings taken in the first 100 d of the subsequent lactation. Antibiotic and anti-inflammatory treatments were recorded for enrolled cows during the study period, as was withdrawal of any cow from the study as a result of death, sale, or culling.
Definition of Terms used for Analysis
Intramammary infection: Cause of clinical mastitis. If an organism was isolated in pure growth, the organism was considered to be the cause of mastitis. A sample was called a 'mixed growth' if there was growth of two or three known mastitis pathogens. A sample was labeled 'contaminated' if more than three organisms were isolated.
Clinical mastitis-quarter case. A single recorded occurrence of clinical mastitis in a quarter. All multiple quarter and recurrent cases were considered a quarter case. Recurrent cases were classified as cases recurring in the same quarter within 5 d of each other and caused by the same pathogen.
Clinical mastitis-cow case. A cow experiencing a mastitis event was a cow case, regardless of the number of quarters affected or the number of times each quarter was affected (caused by the same pathogen). This is synonymous with the proportion of cows affected. Seasonality. The effect of season on mastitis incidence was assessed. Seasons were ascribed as winter (Dec, Jan, Feb); spring (Mar, Apr, May); summer (Jun, Jul, Aug), and autumn (Sep, Oct, Nov).
Parity. The effect of parity on mastitis incidence was assessed. Parities two to five were assessed separately. Parities greater than five were assessed as a group.
Somatic cell counts. Individual cow geometric mean SCC were calculated for recordings before drying off (SCC-PRE) and after calving (SCC-POST). Treatment success was assessed from a combination of the reduction of geometric mean SCC from above to below 200,000 cells/ml or maintenance below 200,000 cells/ ml, as individual cow SCC greater than 200,000 cells/ ml have been reported as being indicative of IMI (Dohoo and Leslie, 1991) .
Results Collation and Statistical Analysis
Results were collated and analyzed with Microsoft Excel, Access, Stata (version 6, Stata Corporation, Texas), Epi-Info (version 6.04b, CDC, Atlanta, GA), and Egret (version 2.0.3, Cytel Software Corp, Cambridge, MA). Mann-Whitney and Wilcoxon tests were used to compare the treatment groups where appropriate. The χ 2 test was used to compare proportions. A significance probability was set at P ≤ 0.05 for a two-tailed test. Herds 1 to 10 were used in all analyses, except those including SCC data when herds 6 and 7 were excluded as individual cow SCC were not recorded.
Unconditional logistic regression was used to model the occurrence of mastitis at cow level to control for potential confounding factors. A strategy was employed as described by Kleinbaum (1994) . The outcome (response) variable was the occurrence of mastitis (yes or no) on one or more occasions in each cow. Four models were fitted with the following outcome variables: 1) all mastitis, 2) gram-negative mastitis, 3) E. coli mastitis, and 4) Non-gram-negative mastitis. Treatment group was used as the exposure variable. The confounding influence on mastitis occurrence of herd, calving season, parity, SCC before drying off, dry period length and days at risk were all assessed. A log transformation of the arithmetic mean of the three SCC (LOG SCC-PRE) readings before drying off was used. Confounders were left in the model if there was an improvement in the accuracy (P value) or precision (confidence intervals) of the explanatory variable. Interactions between covariates were examined and terms remained in the model if there was a significant improvement in the model according to the likelihood ratio statistic (significance probability set at P ≤ 0.05 for a two-tailed test) (Kleinbaum, 1994) . Logistic regression was also performed to analyze the effect of treatment on SCC. A model was fitted with the response variable at cow level being success or failure of treatment as outlined above (yes or no). Confounders and interactions were assessed as for the mastitis outcomes.
The effect of treatment group was deemed significant if inclusion of treatment in the model significantly increased the maximum likelihood according to the likelihood ratio statistic (significance probability set at P ≤ 0.05 for a two-tailed test).
RESULTS
Data was collected from 881 cows (443 in group A, 438 in group B), dried off between March 8, 1999 , and December 20, 1999 , and calving between April 8, 1999 , and April 29, 2000 . Between 49 and 168 cows were recruited from each farm. SCC records were available for 660 cows on eight farms. There were no significant differences between the treatment groups in parity, dry period length, or SCC-PRE (see Table 1 ) as measured using the Mann-Whitney two-sample statistic. A total of 242 cases of clinical mastitis were recorded in the first 100 d of lactation, comprising 221 cow cases.
Univariate Analysis
Clinical mastitis. The number of cases of clinical mastitis, and the proportion of cows affected with clinical mastitis occurring in the first 100 d of lactation in each of the treatment groups is outlined in Table 2 . At the cow level, there was significantly less clinical E. coli (13/443 vs. 26/438; P = 0.023) and coliform (14/443 vs. 31/438; P = 0.006) mastitis in group A. Similarly there was less mastitis overall in group A (94/443 vs. 127/438; P = 0.01). At the individual case level there was a trend toward less clinical S. uberis mastitis in group A (14/443 vs. 25/438; P = 0.10); there were no significant differences between any of the other mastitis pathogens.
Somatic cell count-treatment success. There was no significant difference (P = 0.23) between group A (122,000 cells/ml; median = 33,000) and group B (109,000 cells/ml; median = 29,000) as measured by SCC-POST (Mann-Whitney). When the success of treatment was assessed, there was no significant difference between the groups (273/319 vs. 273/313; P = 0.63). In group A, the SCC rose from below to above 200,000 cells/ml in 27 cows compared with 20 in group B. Intramammary antibiotic dry cow therapy failed to reduce the SCC below 200,000 cells/ml in 20 cows in both groups.
Removal of trial cows. Forty-six cows were withdrawn from the study as a result of culling or death; 21 from group A and 25 from group B. Three cows were culled as a result of mastitis from group A and 11 from group B. Cows from group B were significantly more likely to be culled for reasons associated with mastitis than were cows from group A (3/443 vs. 11/438; P = 0.05).
Logistic Regression Analysis
Clinical mastitis. Mastitis models are shown in Tables 3, 4, 5, and 6. Cows in group B were significantly more likely to develop clinical E. coli mastitis (odds ratio = 2.11, 95% CI = 1.02 to 4.38, P = 0.045) and coliform mastitis (odds ratio = 2.13, 95% CI = 1.05 to 4.32, P = 0.036) but were not more likely to develop clinical mastitis due to other pathogens (P = 0.47), when compared with group A. There was a trend (P = 0.086) towards less mastitis overall in group A. Herd, season, parity, and SCC-PRE were confounding factors in some or all of the individual models.
Somatic cell count-treatment success. There were no significant differences between the two treatment groups (P = 0.21).
DISCUSSION
The incidence and etiology of clinical mastitis recorded on these commercially managed dairy units is probably typical of the average dairy herd in the United Kingdom (Berry, 1998; Kossaibati et al., 1998) . The relatively low bulk milk SCC on these farms explains the relative importance of the coliforms as a cause of clinical mastitis on these farms (Erskine et al., 1988) , Subcolumn means within row, incidence with different superscripts differ (P < 0.05). which was a factor taken into consideration when the farms were selected for this study. We were disappointed that, despite regular farm visits, 17% of clinical cases were not sampled (as measured by comparing samples collected and on farm records); this will have decreased the power of the study, although significant differences were still found. No true negative 'no treatment' control was employed in this study, as it was deemed inappropriate and unethical in view of the wellestablished efficacy of antibiotic dry cow therapy in preventing mastitis during the dry period (Smith et al., 1966) . This study is the first to have demonstrated the clinical efficacy of a dry cow intramammary antibiotic preparation, as measured by a reduction in gram-negative clinical mastitis in the subsequent lactation; cows in group B were twice as likely to develop coliform mastitis. Furthermore, there was a strong trend toward a decrease in overall incidence of mastitis, indicating that noncoliform organisms did not replace coliform organisms and that the dynamics of mastitis were changed. This is of particular interest when one considers the opportunistic environmental pathogens, since removal of one pathogen from the pool of susceptible cows may allow colonization and clinical disease with another. This was not the case in this study, which suggests that the efficacy against gram-positive bacteria of the two products is not significantly different. The average cost of a clinical case of mastitis has been estimated to be GB£175.61 (Kossaibati, 2000) ; this would equate to a clinical mastitis cost reduction of GB£688.39 per 100 cows/yr in group A, based on coliform mastitis alone.
Clinical coliform mastitis was reduced by approximately 50% (by product A) in this study; a previous study by the authors demonstrated that 52% of all clinical coliform mastitis in the first 100 d of lactation occurred in quarters that acquired that infection during the dry period. The findings of the two studies agree and confirm the importance of the dry period in coliform mastitis epidemiology. However, our previous study may have underestimated the importance of the dry period, as the close agreement of the figures would suggest 100% efficacy of the product, which is unlikely to be the case.
Clinical E. coli mastitis has been assumed to arise as a result of invasion, rapid multiplication, and manifestation of clinical signs, as demonstrated in experimental infection (Erskine et al., 1993) . Escherichia coli has also been assumed to behave purely as an opportunistic environmental pathogen (Nemeth et al., 1994) , with all strains being equally capable of colonizing the gland and causing clinical disease. However, this is unlikely as antibiotic dry cow therapy (which only persists until calving) can only influence clinical mastitis occurring during lactation if it is preventing infection and long-term colonization of the gland. The ability of certain strains of E. coli to exhibit long-term colonization of the mammary gland has recently been demonstrated by the authors (Bradley and Green, 2001b) . Another explanation could be if the reduction in coliform mastitis resulted from some other secondary change, such as a persistently high individual cow SCC. This was not the case in this study, as there was not a significant difference between the groups in pre-or postcalving SCC as measured by SCC-PRE and SCC-POST.
In a study such as, this it is important to remember the dual purpose of dry cow therapy, namely to cure existing and prevent new IMI. These were measured in this study by recording SCC before drying off and after calving, and then by monitoring shifts in SCC around the 200,000 cells/ml level which has been shown to correlate with the likelihood of infection (Dohoo and Leslie, 1991) . With these measures, there were no significant differences between the two treatment groups, suggesting that both treatments are equally suitable for maintenance of low milk SCC, an important factor when milk prices in the UK are closely linked to bulk milk SCC levels.
Antibiotic dry cow therapy can only form part of a more holistic approach to dry period udder health management. In the longer term, in light of the concern about the prophylactic use of antibiotics in food producing animals, alternative approaches to minimizing the impact of the dry period need to be investigated (e.g., teat sealants) . In the light of the findings of this study, veterinary practitioners need to reassess the criteria on which they select antibiotic dry cow therapy. This may be especially important in low bulk milk SCC herds, where the primary role of antibiotic dry cow therapy is the prevention of new IMI and where the majority of such infections are likely to be environmental (and particularly coliform) in origin.
